OCA, an FXR agonist, is hypothesized to ameliorate cholestasis by enhancing hepatocellular secretion of conjugated bile acids, improving sinusoidal perfusion and clearance, and thereby reducing hepatocyte exposure to toxic bile acids [27]. This evidence concerns the gene NR1H4 and cholestasis.